IL2 and melanoma: We have previously demonstrated that fusion of collagen-binding proteins lumican or LAIR to extended half-life versions of IL-2 and IL-12 improves efficacy and limits toxicities when directly injected into tumors, even in relatively collagen-sparse B16F10 melanoma tumors, such as those used in this study27,28,36.